Alder Biopharmaceuticals Inc (ALDR.OQ)
16 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2005||Independent Chairman of the Board|
|62||2004||President, Chief Executive Officer, Director|
|56||2016||Executive Vice President, Principal Accounting Officer|
|55||2018||Chief Commercial Officer and Executive Vice President of Corporate Strategy|
|51||2016||Senior Vice President, General Counsel|
- UPDATE 3-Allergan's profit beats; migraine drug succeeds in key study
- BRIEF-Alder Biopharmaceuticals Announces Offering Of $200 Mln Convertible Senior Notes
- BRIEF-Alder Biopharmaceuticals Enters Into European Patent Settlement, Global License Agreement With Teva
- BRIEF-Alder Announces $250 Million Committed Equity Financing
- BRIEF-Alder Says Eptinezumab Met Primary Endpoint In Pivotal Phase 3 Promise 2 Clinical Trial